KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Non-Current Assets for 16 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 73.81% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, up 13.77% year-over-year, with the annual reading at $1.7 billion for FY2025, 73.81% up from the prior year.
  • Non-Current Assets for Q4 2025 was $1.7 billion at Halozyme Therapeutics, up from $892.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $1.7 billion in Q4 2025, with the low at $24.9 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $831.5 million, with a median of $979.9 million recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 4646.49% in 2022, then dropped 16.32% in 2023.
  • Over 5 years, Non-Current Assets stood at $178.1 million in 2021, then skyrocketed by 518.89% to $1.1 billion in 2022, then fell by 10.49% to $986.8 million in 2023, then decreased by 0.88% to $978.1 million in 2024, then surged by 73.81% to $1.7 billion in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $1.7 billion, $892.5 million, and $931.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.